PVPedro O. Flores Villanueva

Pedro O. Flores Villanueva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pedro O. Flores Villanueva has a total of 134 co-authors. Here are the top co-authors by number of shared publications:

  • Heinner Guio

    Laboratorio de Innovación y Desarrollo, Instituto Nacional de Salud, Lima, Perú.

    4 shared publications
  • M J Stadecker

    Department of Pathology, Tufts University School of Medicine , Boston, Massachusetts 02111

    4 shared publications
  • Adele M. Uglialoro

    Dana–Farber Cancer Institute, One Jimmy Fund Way, Boston, MA 02115; The Center for Blood Research, 800 Huntington Avenue, Boston, MA 02115; Departments of Pathology and Medicine, Brigham and Women's Hospital, Boston, MA 02115; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94105; San Francisco Department of Public Health, San Francisco, CA 94102; Liberty Medical, New York, New York 10014; Partners AIDS Research Center, Massachusetts General...

    2 shared publications
  • Edmond J. Yunis

    Dana–Farber Cancer Institute, One Jimmy Fund Way, Boston, MA 02115; The Center for Blood Research, 800 Huntington Avenue, Boston, MA 02115; Departments of Pathology and Medicine, Brigham and Women's Hospital, Boston, MA 02115; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94105; San Francisco Department of Public Health, San Francisco, CA 94102; Liberty Medical, New York, New York 10014; Partners AIDS Research Center, Massachusetts General...

    2 shared publications
  • Eduardo Tarazona-Santos

    Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, 31270-901, Brazil

    2 shared publications
  • Jessica Y. Leung

    Dana–Farber Cancer Institute, One Jimmy Fund Way, Boston, MA 02115; The Center for Blood Research, 800 Huntington Avenue, Boston, MA 02115; Departments of Pathology and Medicine, Brigham and Women's Hospital, Boston, MA 02115; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94105; San Francisco Department of Public Health, San Francisco, CA 94102; Liberty Medical, New York, New York 10014; Partners AIDS Research Center, Massachusetts General...

    2 shared publications

Latest Publications

  • Open Access

    The Peruvian Genome Project: expanding the global pool of genome diversity from South America

    by Heinner Guio, Omar Caceres, Cesar Sanchez, Carlos Padilla, Omar Trujillo, Victor Borda, Luis Jaramillo-Valverde, Julio A. Poterico, Carolina Silva-Carvalho, Mary Horton, et al.

    SUMMARY: The process of inhabiting the Americas by ancestral native American populations involved many individuals settling in the Peruvian Andes and Amazonian regions. Due to Latin American countries representing less than 1% of the human genome data available in public reference databases, the evolution and migration processes involved in adapting to this unique geography have not yet been fully explained. The Peruvian Genome Project is an initiative, started in 2011, to address the underrepresentation of genomic data from native South American populations. This project has collected 1,149 samples from 17 traditional native and 13 mestizo (mixed of native, African, and European ancestry) communities. Currently, 150 whole genomes and 873 array-genotyped individuals have been sequenced from across the geography of Western South America, including coastal, Andes, and Amazonian regions. We discovered 1.6 million novel genetic variants with varying frequencies, indicative of local environmental adaptations and population drift. These novel variants allow us to infer local evolutionary traits and population-specific allele frequencies for people living at different altitudes, as well as varying adaptations to pathogens and living conditions. The Peruvian Genome Project is the result of over a decade of work in sample selection, logistics, and approved regulatory community engagement, designed to enhance the human genome pool of diversity of native Americans. The data collected here enable the targeted characterization of endemic diseases, trait adaptations, and new variants of clinical significance in South America. The Peruvian Genome Project represents a step forward in international and multidisciplinary efforts to make precision medicine more inclusive and accessible for underrepresented communities in Latin America, offering significant potential for drug development and diagnostics in a neglected continent.


  • Open Access

    Evolutionary genomic dynamics of Peruvians before, during, and after the Inca Empire

    by Daniel N. Harris, Wei Song, Amol C. Shetty, Kelly S. Levano, Omar Cáceres, Carlos Padilla, Víctor Borda, David Tarazona, Omar Trujillo, Cesar Sanchez, et al.

    Significance: Through the Peruvian Genome Project we generate and analyze the genomes of 280 individuals where the majority have >90% Native American ancestry and explore questions at the interface of evolutionary genetics, history, anthropology, and medicine. This is the most extensive sampling of high-coverage Native American and mestizo whole genomes to date. We estimate an initial peopling of Peru was rapid and began by 12,000 y ago. In addition, the mestizo populations exhibit admixture between Native American groups prior to their Spanish admixture and was likely influenced by the Inca Empire and Spanish conquest. Our results address important Native American population history questions and establish a dataset beneficial to address the underrepresentation of Native American ancestry in sequencing studies.


  • An Isolated TCR αβ Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8+ T Cells To Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

    by Pedro O Flores-Villanueva, Malathesha Ganachari, Heinner Guio, Jaime A Mejia, Julio Granados

    Lung cancer is a leading cause of cancer-related death among both men and women in the United States, where non–small cell lung cancer accounts for ∼85% of lung cancer. Lung adenocarcinoma (ADC) is the major histologic subtype. The presence of actionable mutations prompts the use of therapies designed to specifically address the deleterious effects of those cancer-driving mutations; these therapies have already shown promise in cases carrying those actionable mutations (∼30%). Innovative therapeutic approaches are needed for the treatment of 70% of patients suffering from lung ADC. Adoptive transfer of CD8+ T cells specific against cancer/testis (CT) Ags, whose protein expression is restricted to the gonads (testis and ovary) and cancerous cells, is an excellent alternative. In this study, we report the isolation of HLA-A*02:01/CT37 peptide–specific α and β TCR chains from a CD8+ T cell clone obtained from a patient suffering from lung ADC. We also report the development of an innovative CD3ζ construct. With those TCR chains and the engineered (modified) CD3ζ chain, we produced a construct that when transduced into CD8+ T cells is capable of redirecting transduced CD8+ T cell cytotoxic activity and IFN-γ secretion against peptide-pulsed autologous cells and HLA-A*02:01–positive and CT37-expressing lung ADC cell lines. Our findings will launch the development of innovative adoptive transfer immunotherapies for the treatment of lung ADC, targeting the most prevalent HLA molecules and CT37 peptides restricted by these molecules.


  • Open Access

    Host gene-encoded severe lung TB: from genes to the potential pathways

    by M Ganachari, H Guio, N Zhao, P O Flores-Villanueva

    We are reporting that the two-locus genotype −2518 macrophage chemoattractant protein (MCP)-1 GG and −1607 matrix metalloproteinase (MMP)-1 2G/2G promotes the expression of hyperinflammation in response to Mycobacterium tuberculosis infection, inducing extensive tissue damage and severe tuberculosis (TB) disease. Carriers of this two-locus genotype have a 13-fold higher chance of developing severe disease and 6.5-fold higher chance of developing permanent lesions, and a 3.864-fold higher chance of delayed response to first-line standardized treatment than carriers of any other relevant combination of genotypes at those two loci. Thus, these persons have an increased likelihood of poor health-related quality of life and of transmitting M. tuberculosis to other members of the community. In addition, through the analysis of human lung tissues, serum/plasma and in vitro experiments, including in vitro infections of THP-1 cells with M. tuberculosis and microarray analysis, we determined that this hyperinflammation state is potentially driven by the MCP-1/MMP-1/PAR-1 pathway. Hence, we are providing markers for the identification of TB cases that may develop severe pulmonary disease and delayed response to treatment, and are providing the basis for development of novel host-targeted clinical interventions to ameliorate the severity of pulmonary TB.


  • CCL2−2518 (A/G) polymorphisms and tuberculosis susceptibility: a meta-analysis [Review article]

    by W-X. Feng, P. O. Flores-Villanueva, I. Mokrousov, X-R. Wu, J. Xiao, W-W. Jiao, L. Sun, Q. Miao, C. Shen, D. Shen, et al.

    BACKGROUND: It has been found that the −2518 C-C motif ligand (CCL)-2 promoter variant increases the risk of developing active tuberculosis (TB). OBJECTIVE: To study the association between −2518 variants and susceptibility to TB. DESIGN: We searched Medline, PubMed and the Wan Fang databases for human genetic studies on whether the −2518 CCL2 polymorphism influences the expression of active TB. Articles published from January 1998 to November 2010 were included. A random effects model was conducted in the meta-analysis. RESULTS: The CCL2−2518G allele (OR 1.51, 95%CI 1.11–2.04, P = 0.008) showed significant association with susceptibility to TB. In genotype analysis, the recessive model (CCL2 genotype GG, OR 1.66, 95%CI 1.19–2.33, P = 0.003) was slightly superior to the dominant model (G carrier genotypes OR 1.53, 95%CI 1.07–2.17, P = 0.018). These observations were prominent among Asians and Latin-Americans of Hispanic ancestry, but not in Africans from Ghana and South Africa. The presence of epistatic genes in one population but not in the other, environmental differences and pathogen virulence may account for this. CONCLUSION: The CCL2−2518G allele increases the risk of developing TB in Asians and Hispanics.


  • Open Access

    Joint Effect of MCP-1 Genotype GG and MMP-1 Genotype 2G/2G Increases the Likelihood of Developing Pulmonary Tuberculosis in BCG-Vaccinated Individuals

    by Malathesha Ganachari, Jorge A. Ruiz-Morales, Juan C. Gomez de la Torre Pretell, Jeffrey Dinh, Julio Granados, Pedro O. Flores-Villanueva

    We previously reported that the – 2518 MCP-1 genotype GG increases the likelihood of developing tuberculosis (TB) in non-BCG-vaccinated Mexicans and Koreans. Here, we tested the hypothesis that this genotype, alone or together with the – 1607 MMP-1 functional polymorphism, increases the likelihood of developing TB in BCG-vaccinated individuals. We conducted population-based case-control studies of BCG-vaccinated individuals in Mexico and Peru that included 193 TB cases and 243 healthy tuberculin-positive controls from Mexico and 701 TB cases and 796 controls from Peru. We also performed immunohistochemistry (IHC) analysis of lymph nodes from carriers of relevant two-locus genotypes and in vitro studies to determine how these variants may operate to increase the risk of developing active disease. We report that a joint effect between the – 2518 MCP-1 genotype GG and the – 1607 MMP-1 genotype 2G/2G consistently increases the odds of developing TB 3.59-fold in Mexicans and 3.9-fold in Peruvians. IHC analysis of lymph nodes indicated that carriers of the two-locus genotype MCP-1 GG MMP-1 2G/2G express the highest levels of both MCP-1 and MMP-1. Carriers of these susceptibility genotypes might be at increased risk of developing TB because they produce high levels of MCP-1, which enhances the induction of MMP-1 production by M. tuberculosis-sonicate antigens to higher levels than in carriers of the other two-locus MCP-1 MMP-1 genotypes studied. This notion was supported by in vitro experiments and luciferase based promoter activity assay. MMP-1 may destabilize granuloma formation and promote tissue damage and disease progression early in the infection. Our findings may foster the development of new and personalized therapeutic approaches targeting MCP-1 and/or MMP-1.


  • Open Access

    A functional promoter polymorphism in monocyte chemoattractant protein–1 is associated with increased susceptibility to pulmonary tuberculosis

    by Pedro O. Flores-Villanueva, Jorge A. Ruiz-Morales, Chang-Hwa Song, Ludmila M. Flores, Eun-Kyeong Jo, Marta Montaño, Peter F. Barnes, Moises Selman, Julio Granados

    We examined the distribution of single nucleotide polymorphisms (SNPs) in nitric oxide synthase 2A, monocyte chemoattractant protein–1 (MCP-1), regulated on activation, normal T cell expressed and secreted, and macrophage inflammatory protein–1α genes in tuberculosis patients and healthy controls from Mexico. The odds of developing tuberculosis were 2.3- and 5.4-fold higher in carriers of MCP-1 genotypes AG and GG than in homozygous AA. Cases of homozygous GG had the highest plasma levels of MCP-1 and the lowest plasma levels of IL-12p40, and these values were negatively correlated. Furthermore, stimulation of monocytes from healthy carriers of the genotype GG with Mycobacterium tuberculosis antigens yielded higher MCP-1 and lower IL-12p40 concentrations than parallel experiments with monocytes from homozygous AA. Addition of anti–MCP-1 increased IL-12p40 levels in cultures of M. tuberculosis–stimulated monocytes from homozygous GG, and addition of exogenous MCP-1 reduced IL-12p40 production by M. tuberculosis–stimulated monocytes from homozygous AA. Furthermore, we could replicate our results in Korean subjects, in whom the odds of developing tuberculosis were 2.8- and 6.9-fold higher in carriers of MCP-1 genotypes AG and GG than in homozygous AA. Our findings suggest that persons bearing the MCP-1 genotype GG produce high concentrations of MCP-1, which inhibits production of IL-12p40 in response to M. tuberculosis and increases the likelihood that M. tuberculosis infection will progress to active pulmonary tuberculosis.


  • HLA-DRB1 alleles encoding the “shared epitope” are associated with susceptibility to developing rheumatoid arthritis whereas HLA-DRB1 alleles encoding an aspartic acid at position 70 of the β-chain are protective in Mexican mestizos

    by J.A Ruiz-Morales, G Vargas-Alarcón, P.O Flores-Villanueva, C Villarreal-Garza, G Hernández-Pacheco, J.K Yamamoto-Furusho, J.M Rodríguez-Pérez, N Pérez-Hernández, M Rull, M.H Cardiel, et al.


  • Open Access

    Associations of MHC Ancestral Haplotypes with Resistance/Susceptibility to AIDS Disease Development

    by Pedro O Flores-Villanueva, Houria Hendel, Sophie Caillat-Zucman, Jay Rappaport, Alberto Burgos-Tiburcio, Sebastien Bertin-Maghit, Jorge A Ruiz-Morales, Maria E Teran, Juan Rodriguez-Tafur, Jean-FrançoIs Zagury

    We tested the association of MHC ancestral haplotypes with rapid or slow progression to AIDS by comparing their frequencies in the French genetics of resistance/susceptibility to immunodeficiency virus cohort with that reported in a control French population. Seven ancestral haplotypes were identified in the genetics of resistance/susceptibility to immunodeficiency virus cohort with a frequency >1%. The 8.1 (odds ratio (OR) = 3, p = 0.006), 35.1 (OR = 5.7, p = 0.001), and 44.2 (OR = 3.4, p = 0.007) ancestral haplotypes were associated with rapid progression, whereas the 35.2 (OR = 3.6, p = 0.001), 44.1 (OR = 5.4, p < 10−4), and 57.1 (OR = 5.8, p < 10−4) ancestral haplotypes were associated with slow progression to AIDS. Although the frequency of each ancestral haplotype is low in the population, the OR were quite higher than those previously obtained for single HLA allele associations, with some p values as low as 10−4. The analysis of the recombinant fragments of these haplotypes allowed the identification of the MHC regions in the 35.1, 35.2, and 44.2 haplotypes associated with rapid progression to AIDS and the MHC regions of the 44.1 and 57.1 haplotypes associated with slow progression to AIDS. Previous studies have identified single HLA alleles associated with disease progression. Our results on recombinant fragments confirm the direct role of HLA-B35 in rapid progression. Associations with HLA-A29 and -B57 might be due to linkage disequilibrium with other causative genes within the MHC region.


  • Linkage disequilibrium between HLA-DPB1 alleles and retinoid X receptor β haplotypes

    by Ricardo Rajsbaum, Dolores Fici, Deborah A Boggs, Patricia A Fraser, Pedro O Flores-Villanueva, Zuheir L Awdeh